Anti-RED1 抗体 (ab64830)
Key features and details
- Rabbit polyclonal to RED1
- Suitable for: ELISA, WB, IHC-P, ICC/IF
- Reacts with: Mouse, Human
- Isotype: IgG
製品の概要
-
製品名
Anti-RED1 antibody
RED1 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to RED1 -
由来種
Rabbit -
アプリケーション
適用あり: ELISA, WB, IHC-P, ICC/IFmore details -
種交差性
交差種: Mouse, Human
交差が予測される動物種: Rat
-
免疫原
Synthetic peptide derived from an internal sequence of human RED1.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
バッファー
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride -
Concentration information loading... -
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab64830の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| ELISA |
Use at an assay dependent concentration.
|
|
| WB |
1/500 - 1/1000. Detects a band of approximately 81 kDa (predicted molecular weight: 81 kDa).
|
|
| IHC-P |
Use at an assay dependent concentration. PubMed: 24608178
|
|
| ICC/IF | (1) |
Use a concentration of 1 - 5 µg/ml.
|
| 特記事項 |
|---|
|
ELISA
Use at an assay dependent concentration. |
|
WB
1/500 - 1/1000. Detects a band of approximately 81 kDa (predicted molecular weight: 81 kDa). |
|
IHC-P
Use at an assay dependent concentration. PubMed: 24608178 |
|
ICC/IF
Use a concentration of 1 - 5 µg/ml. |
ターゲット情報
-
機能
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. -
組織特異性
Highly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). Isoform 5 is high expressed in hippocampus and colon. Isoform 5 is expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen. -
配列類似性
Contains 1 A to I editase domain.
Contains 2 DRBM (double-stranded RNA-binding) domains. -
細胞内局在
Nucleus. Nucleus > nucleolus. Shuttles between nucleoli and the nucleoplasm. - Information by UniProt
-
参照データベース
- Entrez Gene: 104 Human
- Entrez Gene: 110532 Mouse
- Entrez Gene: 25367 Rat
- Omim: 601218 Human
- SwissProt: P78563 Human
- SwissProt: Q91ZS8 Mouse
- SwissProt: P51400 Rat
- Unigene: 474018 Human
see all -
別名
- ADARB 1 antibody
- ADARB1 antibody
- 1700057H01Rik antibody
see all
画像
-
Western blot - Anti-RED1 antibody (ab64830)All lanes : Anti-RED1 antibody (ab64830) at 1/500 dilution
Lane 1 : HepG2 cell extract (5-30 µg total protein)
Lane 2 : HepG2 cell extract (5-30 µg total protein) ) with 5-10 µg of the immunising peptide
Predicted band size: 81 kDa
Observed band size: 81 kDa -
Immunocytochemistry/ Immunofluorescence - Anti-RED1 antibody (ab64830)ICC/IF image of ab64830 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab64830, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (7)
ab64830 は 7 報の論文で使用されています。
- van der Kwast RVCT et al. Adenosine-to-Inosine Editing of Vasoactive MicroRNAs Alters Their Targetome and Function in Ischemia. Mol Ther Nucleic Acids 21:932-953 (2020). PubMed: 32814251
- Filippini A et al. Differential Enzymatic Activity of Rat ADAR2 Splicing Variants Is Due to Altered Capability to Interact with RNA in the Deaminase Domain. Genes (Basel) 9:N/A (2018). PubMed: 29419780
- Huang H et al. Tissue-selective restriction of RNA editing of CaV1.3 by splicing factor SRSF9. Nucleic Acids Res 46:7323-7338 (2018). PubMed: 29733375
- Shanmugam R et al. SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates. Nucleic Acids Res 46:7379-7395 (2018). PubMed: 29992293
- Xiang JF et al. N6-Methyladenosines Modulate A-to-I RNA Editing. Mol Cell 69:126-135.e6 (2018). PubMed: 29304330
- Filippini A et al. Absence of the Fragile X Mental Retardation Protein results in defects of RNA editing of neuronal mRNAs in mouse. RNA Biol 14:1580-1591 (2017). PubMed: 28640668
- Wang AL et al. Down-regulation of the RNA editing enzyme ADAR2 contributes to RGC death in a mouse model of glaucoma. PLoS One 9:e91288 (2014). IHC-P ; Mouse . PubMed: 24608178